Results from Sort-Out IV study, comparing Cordis' Cypher Sirolimus-eluting coronary stent and Abbott’s Xience V Everolimus-eluting stent in the primary endpoint of MACE (major acute coronary events) at nine months, were released by the investigators of the study.
Sort Out IV, a randomised trial, was designed to test whether the Xience V stent is non-inferior to the Cypher stent.
Reportedly, both drug-eluting stents performed better than planned for the composite endpoint of MACE (4.9% for Xience V stent vs 5.2% for Cypher stent); these data support the non-inferiority of the Xience stent over the Cypher stent.
Cordis Global Research and Development head and chief scientific officer Campbell Rogers said that the Sort Out consortium has used Cypher Stent as the comparator in a number of studies and to date, no newer stent has proven a benefit over Cypher Stent in terms of safety or efficacy.
“The Sort Out IV trial demonstrates that both drug eluting stents perform extremely well,” Rogers said.